Redhill Biopharma Adds Second GI Product
Edison | Apr 07, 2017 03:25AM ET
Yesterday Redhill (NASDAQ:RDHL) announced an agreement with US-based medical food developer and manufacturer Entera Health for exclusive rights to market EnteraGam in the US. In exchange, RedHill will pay tiered royalties, but notably no upfront or milestone payments. EnteraGam is an FDA-regulated medical food intended for the dietary management of chronic diarrhea and has to be administered under medical supervision. This is the second product RedHill has added to its commercial portfolio after the co-promotion deal for Donnatal with Concordia Healthcare in January 2017.
Originally developed by Entera Health, EnteraGam was launched in 2013 and targeted diarrhoea-predominant irritable bowel syndrome (IBS-D) patients, although increasing data suggest it can be used for chronic diarrhoea due to various causes (RedHill will be able to market for all indications). EnteraGam is a serum-derived bovine immunoglobulin/protein isolate (SBI) with a proposed mechanism of action of restoring gut balance. RedHill already has one product, Bekinda (a once-daily oral formulation of ondansetron), for IBS-D in Phase II, although a drug with a different mechanism of action and therefore not a direct competitor. Instead, we see operational synergy as RedHill will gain experience and know-how in targeting IBS-D patients ahead of the launch of Bekinda, presuming supportive data.
To read the entire report Please click on the pdf File Below
Redhill Biopharma - Second GI Product Added To Commercial Portfolio
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.